UCB

UCB was founded in 1928 as a chemical company and has since evolved into a leader in the fields of neurology and immunology. UCB's headquarter is in Brussels, Belgium, and it has operations in more than 40 countries. UCB's market cap is about 16 billion euros as of May 2023.

UCB is committed to creating value for patients, society and shareholders through innovation, collaboration and excellence. UCB has received many awards and recognitions for its achievements in research and development, corporate responsibility and diversity. Some of the recent awards include the European Mediscience Award for Best Technology in 2022, the Corporate Knights Global 100 Most Sustainable Corporations in 2021 and the Catalyst Award for Advancing Women in Business in 2020.

UCB is also involved in many projects and initiatives that aim to improve the lives of people living with severe diseases. For example, UCB is a partner of the Innovative Medicines Initiative (IMI), a public-private partnership that supports the development of new medicines and therapies. UCB is also a member of the Access Accelerated initiative, a global partnership that works to improve access to non-communicable disease prevention, diagnosis and treatment in low- and middle-income countries.

Foundation: 1928
Headquarters: Brussels, Belgium
Website: https://www.ucb.com/